Abstract 2979
Background
Despite advances in early detection, diagnosis, and treatment of oral squamous cell carcinoma (OSCC), the survival for patients with early stage remains at approximately 80% for the past 30 years. Regional lymph node metastasis is an important prognostic factor. Therefore, early detection of the cervical lymph nodes metastasis is expected to further improve survival. Sentinel lymph node biopsy (SLNB) is a widely accepted procedure in various human malignancies. In clinically N0 (cN0) early OSCC cases, SLNB has received considerable attention for its role in deciding whether to perform neck dissection. The objective in this study is to investigate the topographical distribution of sentinel lymph nodes (SLNs) and occult metastatic lymph nodes in early tongue squamous cell carcinoma (TSCC).
Methods
A total of 64 patients with T1/2N0 TSCC underwent SLNB between 2001 and 2016. The location of SLNs was determined by radioisotope (RI) method with preoperative lymphoscintigraphy and intraoperative use of a handheld gamma probe, and evaluated by histopathological and genetic examinations. Patients with metastatic lymph nodes were treated with completion neck dissection. Excised lymph nodes were grouped into the neck level according to the international guidelines.
Results
SLNs were successfully identified with RI method (100%). The rate of SLN identified side was 84.5% in ipsilateral, 12.1% in bilateral, and 3.4% in contralateral. Nine of 64 patients (14.1%) had metastasis-positive SLN. Six patients with negative SLN developed the latent neck lymph node metastasis. There was no patients with metastatic involvement of neck level IV and V. The sensitivity, specificity, and accuracy was 60% (9/15), 100% (49/49), and 90.6% (58/64), respectively.
Conclusions
SLNB is a minimally invasive and highly reliable method staging the cN0 for patients with early OSCC. Completion neck dissection of level I-III in SLNB-positive patients might be sufficient in patients with early TSCC. Our study showed that SLNB was helpful in clarifying unexpected bilateral or contralateral metastatic drainage patterns. SLNB provides more accurate staging than elective neck dissection or wait and see policy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract
1707 - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)
Presenter: Keisuke Kirita
Session: Poster Display session 3
Resources:
Abstract
3594 - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
744 - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-l1.
Presenter: Sheng Yu
Session: Poster Display session 3
Resources:
Abstract
2350 - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Presenter: Rika Kizawa
Session: Poster Display session 3
Resources:
Abstract
5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.
Presenter: Javier Pérez-peña
Session: Poster Display session 3
Resources:
Abstract
6127 - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations
Presenter: Lele Song
Session: Poster Display session 3
Resources:
Abstract
1310 - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody.
Presenter: Motoo Nomura
Session: Poster Display session 3
Resources:
Abstract
2286 - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment
Presenter: Nicholas Willumsen
Session: Poster Display session 3
Resources:
Abstract
4107 - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Presenter: Julie Stein
Session: Poster Display session 3
Resources:
Abstract